4//SEC Filing
LOF PARTNERS LLC 4
Accession 0001181431-13-007052
CIK 0000810084other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 10:06 AM ET
Size
14.7 KB
Accession
0001181431-13-007052
Insider Transaction Report
Form 4
Transactions
- Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+11,388$113,880→ 11,388 totalExercise: $0.04From: 2013-01-24→ Common Stock (3,253,714 underlying) - Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+63,612$636,120→ 63,612 totalExercise: $0.04From: 2013-01-24→ Common Stock (18,174,857 underlying)
LOF PARTNERS LLC
Other
Transactions
- Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+11,388$113,880→ 11,388 totalExercise: $0.04From: 2013-01-24→ Common Stock (3,253,714 underlying) - Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+63,612$636,120→ 63,612 totalExercise: $0.04From: 2013-01-24→ Common Stock (18,174,857 underlying)
GALE JAMES C
Director
Transactions
- Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+11,388$113,880→ 11,388 totalExercise: $0.04From: 2013-01-24→ Common Stock (3,253,714 underlying) - Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+63,612$636,120→ 63,612 totalExercise: $0.04From: 2013-01-24→ Common Stock (18,174,857 underlying)
SMH CAPITAL INC.
10% OwnerOther
Transactions
- Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+63,612$636,120→ 63,612 totalExercise: $0.04From: 2013-01-24→ Common Stock (18,174,857 underlying) - Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+11,388$113,880→ 11,388 totalExercise: $0.04From: 2013-01-24→ Common Stock (3,253,714 underlying)
Footnotes (4)
- [F1]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II, L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
- [F2]These securities are owned directly by Life Sciences Opportunities Fund II (Institutional), L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II (Institutional), L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
- [F3]Series H Convertible Preferred Stock was issued pursuant to the terms of a Purchase Agreement dated as of January 24, 2013. The Shares are convertible at any time by the purchasers into Commn Stock at the rate of $0.035 per share(subject to anti-dilution adjustments) or approximately 285.71 shares. LOF and LOFI paid cash for the shares.
- [F4]None
Documents
Issuer
BIOJECT MEDICAL TECHNOLOGIES INC
CIK 0000810084
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001280952
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 10:06 AM ET
- Size
- 14.7 KB